Their expertise ensures that each patient receives a personalized treatment plan for optimal results
We built meal bundles that match
Application expansion possibilities Indications for local fat reduction: It is suitable for areas with local fat accumulation such as the abdomen and thighs
ADOCIA Reports Second Quarter 2026 Financial Results and Provides a Business Update ADOCIA Reports Second Quarter 2026 Financial Results and Provides a Business Update Cash position of 9.7 million as of June 30, 2026 Shareholder loan agreement signed with Vester Finance in April 2026, securing a cash runway until the beginning of Q2 2027 BioChaperone feasibility studies with positive results enabling to engage in discussions for the next steps with large pharmaceutical companies Regulatory News: Adocia (Euronext Paris: FR0011184241 ADOC, the Company), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the second quarter of 2026 and provides a business update
While preliminary safety data appears promising, more comprehensive human studies are needed to establish definitive dosing guidelines and safety parameters
This 28-day window is why vial size and reconstitution volume need to be planned together
